Notice of Annual Shareholders Meeting 2018 Proxy Form Dear Shareholders of Akari Therapeutics, Plc: You are cordially invited to attend (and …
[Read more...] about Notice of Annual Shareholders Meeting & Proxy Form
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve …
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
NEW YORK and LONDON, June 15, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of …
Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
NEW YORK and LONDON, May 21, 2018 - Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of …
[Read more...] about Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress
Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naïve Trial CAPSTONE, the Phase III Naïve PNH Trial Expected to …
